Loss of mucosal tolerance to glycoprotein 2 isoform 1 is a potential novel diagnostic biomarker for cholangiocarcinoma
Digestive and Liver Disease · 2025
DOI: 10.1016/j.dld.2024.05.027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive and Liver Disease, 2025. Verfasst von Chang-Sheng Xia und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Anti-glycoprotein 2 (anti-GP2) IgA and antineutrophil-cytoplasmic antibodies to proteinase 3 (PR3-ANCA) have been reported as predictive markers of cholangiocarcinoma (CCA) in patients with primary sclerosing cholangitis (PSC), but their prevalence in CCA patients without PSC remains unclear. METHODS: This study involved Asian discovery (n = 118) and European validation (n = 38) cohorts of CCA patients without PSC, alongside 49 Asian and 82 European pancreatic ductal adenocarcinoma (PDAC) patients, 21 with benign pancreatic neoplasms (BPN) and 45 with hepatocellular carcinoma (HCC), and 157 healthy controls (HC) from Asia and Europe. We analyzed the prevalence of PR3-ANCA, IgA and IgG against GP21 and GP24, and the CA19-9 levels. RESULTS: Anti-GP21 IgA was the most prevalent in both CCA cohorts (discovery: 55.1 %; validation: 42.1 %) and significantly higher than in other groups except PDAC (all p < 0.05). It demonstrated the best diagnostic performance in distinguishing CCA from disease controls and HC, outperforming tumor markers. No significant correlation was found between anti-GP21 IgA levels and CA19-9 levels. CONCLUSION: Our findings show that anti-GP21 IgA revealing the loss of mucosal tolerance is a potential novel diagnostic biomarker for CCA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Peking University People's Hospital, Beijing, China.
- Department of Medicine II, Saarland University Medical Center, Saarland University, Homburg, Germany; Laboratory of Metabolic Liver Diseases, Department of General, Transplant and Liver Surgery, Centre for Preclinical R…
- Department of Gastroenterology and Hepatology with Internal Disease Unit, Teaching Hospital No 1 in Rzeszów, Medical Department, University of Rzeszów, Poland.
- Laboratory of Metabolic Liver Diseases, Department of General, Transplant and Liver Surgery, Centre for Preclinical Research, Medical University of Warsaw, Warsaw, Poland.
- Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Poland.
- Liver and Internal Medicine Unit, Department of General, Transplant and Liver Surgery, Medical University of Warsaw, 02-091 Warsaw, Poland; Translational Medicine Group, Pomeranian Medical University, Szczecin, Poland.
Zitieren
APA
Xia, C. S., Krawczyk, M., Di, C., Krupa, Ł., Kruk, B., Krawczyk, P., Milkiewicz, P., Bao, H., He, X., Liu, D., Fan, C., Nasser, A., Lopens, S., Weiss, F. U., Frost, F., Schierack, P., Roggenbuck, D., & Liu, Y. (2025). Loss of mucosal tolerance to glycoprotein 2 isoform 1 is a potential novel diagnostic biomarker for cholangiocarcinoma. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2024.05.027
Vancouver
Xia CS, Krawczyk M, Di C, Krupa Ł, Kruk B, Krawczyk P, et al. Loss of mucosal tolerance to glycoprotein 2 isoform 1 is a potential novel diagnostic biomarker for cholangiocarcinoma. Digestive and Liver Disease. 2025. doi:10.1016/j.dld.2024.05.027
BibTeX
@article{Xia2025,
author = {Xia, Chang-Sheng and Krawczyk, Marcin and Di, Chun and Krupa, Łukasz and Kruk, Beata and Krawczyk, Piotr and Milkiewicz, Piotr and Bao, Huizhang and He, Xiao and Liu, Damin and Fan, Chunhong and Nasser, Abdullah and Lopens, Steffi and Weiss, Frank Ulrich and Frost, Fabian and Schierack, Peter and Roggenbuck, Dirk and Liu, Yudong},
title = {Loss of mucosal tolerance to glycoprotein 2 isoform 1 is a potential novel diagnostic biomarker for cholangiocarcinoma},
journal = {Digestive and Liver Disease},
year = {2025},
doi = {10.1016/j.dld.2024.05.027}
}
EUVIMED